Avenda Health to Present at the Annual Meeting of the Engineering and Urology Society During the 2019 American Urology Association Annual Meeting

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Avenda Health, a software and medical device company developing an AI-based focal laser ablation system to offer patients a personalized prostate cancer treatment, today announced the company will present multiple abstracts at the Annual Meeting of the Engineering and Urology Section (EUS), taking place during the 2019 American Urology Association (AUA) Annual Meeting, May 3 – 6, in Chicago.

Avenda Health’s investigational, image-guided focal laser ablation system is designed to treat localized prostate cancer in a urologist’s office. In conjunction with AI-based margin prediction algorithms, it uses a laser and a proprietary optical and thermal sensor to precisely target and treat just the prostate tumor – not the entire prostate. The goal is for this targeted ablation to minimize the impact on healthy tissues, without compromising urinary or sexual function.

“Today’s standard treatment approaches typically involve removing or treating the entire prostate gland. Our investigational technology is office-based and uses imaging, artificial intelligence, and laser ablation to treat only the tumor with a safety margin, minimizing side effects on the patient,” said Shyam Natarajan, co-founder and CEO of Avenda Health. “We look forward to sharing data with the urology community at the EUS meeting that demonstrate the potential of our AI-driven focal laser ablation technology in treating prostate cancer while preserving quality of life.”

EUS at AUA presentations taking place May 5th at the Marriott Marquis include:

• “Development of an Office-Based Laser Ablation System for Prostate Cancer” will be presented by Josh Shubert, Software Engineer, Avenda Health.
  – Poster Session #24, Great Lakes Ballroom B at 1:30 – 2:30 p.m. CT

• “Improving Prostate Cancer Margin Prediction Through Machine Learning,” awarded 2019 Best Paper by the Engineering and Urology Society, will be presented by Dr. Alan Priester, David Geffen School of Medicine, UCLA.
  – Poster Session #36, Great Lakes Ballroom B at 2:30 – 3:30 p.m. CT

• “MRI Changes After In-Office Focal Cryoablation of Prostate Cancer: A Pilot Study” will be presented by Steve Zhou, David Geffen School of Medicine, UCLA.
  – Poster Session #47, Great Lakes Ballroom B at 2:30 – 3:30 p.m. CT

Additionally, the company will be demonstrating its software and focal laser ablation technology at booth #1413 throughout the duration of the AUA meeting.

About Avenda Health

Avenda Health is the only image-guided ablation system (pending FDA clearance) that leverages artificial intelligence to treat only the tumor, minimizing the side effects of the treatment on the patient. Unlike other options, this approach has the potential to offer patients a personalized treatment performed in-office using local anesthesia, potentially allowing them to quickly return to their daily activities without compromising their quality of life. Also, because this is a minimally invasive and local treatment, it doesn’t close the door for future treatment options should patients need it.

For more information visit avendahealth.com and follow on Twitter at @AvendaHealth.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190425005345/en/